The median overall survival were unable to calculate in some patients because less than 50% of patients died until the last time of follow-up. The median overall survival of ASC.
Background: Metastatic renal cell carcinoma (mRCC) patients with bone metastases (BM) are at high risk for skeletal related events and have a poorer outcome when treated with vascular endothelial grow
